<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181155</url>
  </required_header>
  <id_info>
    <org_study_id>IRB: 04-10-12-06</org_study_id>
    <secondary_id>5R01HL061912-14</secondary_id>
    <nct_id>NCT00181155</nct_id>
  </id_info>
  <brief_title>Intravenous Allopurinol in Heart Failure</brief_title>
  <official_title>Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves
      heart metabolism in patients with heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xanthine oxidase have been reported to improve mechano-energetic coupling in failing hearts.
      The investigators developed a means to directly measure creatine kinase flux, the major
      energy reserve of the heart, in the human heart exploiting new magnetic resonance
      technologies.

      The investigators propose to study 10 healthy subjects and up to 25 with heart failure
      (dilated cardiomyopathy) before and after a single 300mg IV infusion of allopurinol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion</measure>
    <time_frame>Onset of imaging acquisition.</time_frame>
    <description>Magnetic resonance spectroscopy (MRS) Measurement of Myocardial CK Flux Pre Intravenous Allopurinol Infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial CK Flux Post Intravenous Allopurinol Infusion.</measure>
    <time_frame>acute (within 15 minutes of single infusion)</time_frame>
    <description>The mean rate of adenosine triphosphate (ATP) flux through the creatine kinase reaction in the heart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac PCr/ATP Pre Intravenous Infusion</measure>
    <time_frame>Onset of image acquisition.</time_frame>
    <description>The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac PCr/ATP Post Intravenous Infusion</measure>
    <time_frame>acute (within 15 minutes of single infusion)</time_frame>
    <description>The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>intravenous infusion of allopurinol (300mg)</description>
    <arm_group_label>Allopurinol</arm_group_label>
    <other_name>Aloprim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion of 50 ml dose of 5% dextrose</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>5% Dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  The patient is willing and able to provide informed consent

          -  Clinical diagnosis of chronic heart failure

          -  Ejection fraction (EF) &lt; 40% by echocardiography, nuclear multigated acquisition
             (MUGA) or cath ventriculography

          -  No significant coronary disease at cardiac catheterization

          -  New York Heart Association (NYHA) Class I-IV symptoms

          -  Clinical stabilization for two weeks if following recent congestive heart failure
             (CHF) decompensation.

        Exclusion Criteria:

          -  Metallic implant prohibiting magnetic resonance (MR) evaluation

          -  Inability to lie flat for MR study

          -  Administration of additional investigational drugs

          -  Calculated creatinine clearance &lt; 50 mL/min

          -  Allergy to allopurinol

          -  Current gout flare

          -  Currently taking oral allopurinol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>November 11, 2015</results_first_submitted>
  <results_first_submitted_qc>January 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2016</results_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Robert G. Weiss</investigator_full_name>
    <investigator_title>Professor of Medicine and Radiology</investigator_title>
  </responsible_party>
  <keyword>metabolism</keyword>
  <keyword>congestive heart failure</keyword>
  <keyword>allopurinol</keyword>
  <keyword>Adenosine triphosphate (ATP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with Non-Ischemic Cardiomyopathy were recruited as approved by the Johns Hopkins Institutional Review Board for Human Investigation.</recruitment_details>
      <pre_assignment_details>The study drug allocation was randomized in a 4:1 fashion by the research pharmacy. Participants were randomized to Placebo only for the purposes of blinding; Adverse Events were collected for the Placebo arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Allopurinol</title>
          <description>Each participant underwent magnetic resonance spectroscopy before and following infusion of either allopurinol 300mg or placebo.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Each participant underwent magnetic resonance spectroscopy before and following infusion of either allopurinol 300mg or placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Allopurinol</title>
          <description>We randomized patients with nonischemic cardiomyopathy in a double-blind fashion to allopurinol (300 mg intravenously) or placebo infusion, 4-to-1, the latter for purposes of blinding only. The myocardial concentrations of ATP and creatine phosphate (PCr) and the rate of adenosine triphosphate (ATP) synthesis through CK (CK flux) were determined by 31-Phosphorus (31P) magnetic resonance spectroscopy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion</title>
        <description>Magnetic resonance spectroscopy (MRS) Measurement of Myocardial CK Flux Pre Intravenous Allopurinol Infusion</description>
        <time_frame>Onset of imaging acquisition.</time_frame>
        <population>Data were analyzed for all participants who completed the MRS per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Each participant underwent baseline MRS imaging prior to infusion of Aloprim 300 mg in 50 cc of 5% Dextrose.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion</title>
          <description>Magnetic resonance spectroscopy (MRS) Measurement of Myocardial CK Flux Pre Intravenous Allopurinol Infusion</description>
          <population>Data were analyzed for all participants who completed the MRS per protocol.</population>
          <units>umol/g/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac PCr/ATP Pre Intravenous Infusion</title>
        <description>The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.</description>
        <time_frame>Onset of image acquisition.</time_frame>
        <population>Data were analyzed for all participants who completed the MRS per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Each participant underwent baseline MRS imaging prior to infusion of Aloprim 300 mg in 50 cc of 5% Dextrose.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac PCr/ATP Pre Intravenous Infusion</title>
          <description>The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.</description>
          <population>Data were analyzed for all participants who completed the MRS per protocol.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Myocardial CK Flux Post Intravenous Allopurinol Infusion.</title>
        <description>The mean rate of adenosine triphosphate (ATP) flux through the creatine kinase reaction in the heart.</description>
        <time_frame>acute (within 15 minutes of single infusion)</time_frame>
        <population>Data were analyzed for all participants who completed the MRS per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Allopurinol</title>
            <description>Infused Aloprim 300 mg in 50cc 5% dextrose. Post MRS data acquired on each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial CK Flux Post Intravenous Allopurinol Infusion.</title>
          <description>The mean rate of adenosine triphosphate (ATP) flux through the creatine kinase reaction in the heart.</description>
          <population>Data were analyzed for all participants who completed the MRS per protocol.</population>
          <units>umol/g/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.007</p_value>
            <p_value_desc>vs. baseline</p_value_desc>
            <method>Two-sided paired t tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac PCr/ATP Post Intravenous Infusion</title>
        <description>The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.</description>
        <time_frame>acute (within 15 minutes of single infusion)</time_frame>
        <population>Data were analyzed for all participants who completed the MRS per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Allopurinol</title>
            <description>Infused Aloprim 300 mg in 50cc of 5% dextrose. Post infusion MRS data acquired on each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac PCr/ATP Post Intravenous Infusion</title>
          <description>The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.</description>
          <population>Data were analyzed for all participants who completed the MRS per protocol.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.02</p_value>
            <p_value_desc>vs. baseline</p_value_desc>
            <method>Two-sided paired t tests</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 - Intravenous Allopurinol</title>
          <description>Each participant received pre and post MRS images following infusion of 50 cc of Aloprim 300mg in 5% Dextrose.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 - Placebo</title>
          <description>Each participant received pre and post MRS images following infusion of 50 cc of 5% Dextrose (equivalent volume to active treatment arm).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of the current study include the small placebo group sample size and the etiologic heterogeneity of the nonischemic cardiomyopathy group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert G. Weiss, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-1703</phone>
      <email>rweiss@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

